Present Title & Affiliation
- Professor of Clinical Medicine, Division of Myeloma, Sylvester Myeloma Institute, University of Miami
- Associate Director, Sylvester Myeloma Institute, University of Miami
- Assistant Director, Clinical Research Services, Office of Clinical Research, Sylvester Comprehensive Cancer Center, Miami, FL, USA
| Year | Degree | Institution | Location | |||
|---|---|---|---|---|---|---|
| 2003 | MD, Medicine | Boston University School of Medicine | Boston University School of Medicine | |||
| 1999 | MD, Medicine | Boston University School of Medicine | Boston University School of Medicin | |||
Education & Training | ||||||
2012 | Fellowship, Hematology & Medical Oncology | National Institutes of Health (NIH) | Bethesda, MD, USA | |||
| 2006 | Residency, Internal Medicine | Wilford Hall Medical Center | USA | |||
Licensures & Certifications | ||||||
Medical License | State of Florida | ME148320 | ||||
Medical License | State of Virginia | 0101236863 | ||||
| Board Certification, Internal Medicine | ABIM | Certified | ||||
Board Certification, Medical Oncology | ABIM | Certified | ||||
| Board Eligibility, Hematology | ABIM | Board Eligible | ||||
Professional Positions & Employment | ||||||
| Present | Associate Director, Sylvester Myeloma Institute | University of Miami | Miami, FL | |||
| Present | Assistant Director, Clinical Research Services | Sylvester Comprehensive Cancer Center | Miami, FL | |||
#colspan# | Head, Myeloma Program, Lymphoid Malignancies Branch | National Cancer Institute (NCI) | Bethesda, MD | |||
#colspan# | Associate Director, FDA–NCI Clinical Investigator Program | U.S. Food and Drug Administration | USA | |||
#colspan# | Physician–Scientist, NCI Intramural Research Program | NIH | USA | |||
#colspan# | Internal Medicine Attending & Assistant Professor | U.S. Air Force Medical Corps | USA | |||
| Active Duty Physician (including deployment for Operation Iraqi Freedom) | U.S. Air Force | USA | ||||
Professional Organizations & Activities | ||||||
| Reviewer | American Cancer Society IRG | 2023 | ||||
Reviewer | JCO Clinical Cancer Informatics | 2023 | ||||
Reviewer | Leukemia | Leukemia | ||||
| Nature Medicine | 2022 | |||||
| The Lancet | 2021 | |||||
Reviewer | Blood | 2020 | ||||
| FDA Regulatory Science Research Grants | 2019 | |||||
| JAMA Oncology | 2016 | |||||
| FDA Critical Path Initiative Grants | 2015 | |||||
| DoD Congressionally Directed Prostate Cancer Panel | 2007 | |||||
Honors & Awards | ||||||
| Honor Award | FDA Center for Drug Evaluation & Research | |||||
| Commissioner’s Special Citation Award | U.S. FDA | |||||
| Distinguished Alumni Rising Star Award | Boston University, Biology Department | |||||
| Breakthrough Therapy Program Group Recognition Award | U.S. FDA | |||||
| Outstanding Service Award | FDA – CDRH | |||||
Excellence in Communication Award | FDA – CDER | |||||
Outstanding Service Award | U.S. FDA | |||||
Ten Years Federal Government Service Recognition | U.S. Government | |||||
Phi Beta Kappa Honor Society | Boston University | |||||
Early Intervention in Myeloma | Identifying genomic signatures to distinguish early MM vs MGUS/smoldering disease | |||||
| Genomic Profiling | Applying next-generation sequencing for minimal residual disease (MRD) monitoring | |||||
| Myeloma Precursor Biology | Studying racial and ethnic differences in incidence, onset, and outcomes | |||||
| Population Cohort Development | Building a South Florida myeloma precursor cohort focusing on Latin populations | |||||
| Novel Therapeutics | Development of new drug and immune-based therapies for myeloma | |||||
| Development of new drug and immune-based therapies for myeloma | ||||||